KR960705582A - 백신 설계 및 제조 방법(vaccine design and production) - Google Patents
백신 설계 및 제조 방법(vaccine design and production)Info
- Publication number
- KR960705582A KR960705582A KR1019960702306A KR19960702306A KR960705582A KR 960705582 A KR960705582 A KR 960705582A KR 1019960702306 A KR1019960702306 A KR 1019960702306A KR 19960702306 A KR19960702306 A KR 19960702306A KR 960705582 A KR960705582 A KR 960705582A
- Authority
- KR
- South Korea
- Prior art keywords
- ile
- val
- ala
- gly
- leu
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 9
- 208000004396 mastitis Diseases 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 3
- 241000894006 Bacteria Species 0.000 claims abstract 2
- 230000000813 microbial effect Effects 0.000 claims abstract 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 4
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 claims 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 235000019260 propionic acid Nutrition 0.000 claims 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
- 241000192125 Firmicutes Species 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
Abstract
유방 연성 상피세포에 점착하는 박테리아와 관계된 단백질로부터 유래된 펩티드는 유방염을 예방하는 백신 제조에 사용할 수 있다. 미생물 점착을 결정하는 방법은 바람직한 백신 설계를 제공한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 하기 일반식을 갖는 유방염 백신 펩티드 :R1-R2-R3-R4-R5-R6-R7-R8-Gly-R10-Gly-R12-R13-Gly-R15-R16-Ala-R18-Arg-Ala-R21-Gln-Gly-R24상기 식에서, R1은 수소 또는 C1-C16카복실산이고: R2는 Ala, Gly, Ser 또는 프로피온산이고; R3은 Val, Ile, Leu 또는 D-Val이고; R4는 Lys 또는 Arg이고: R5는 Val, Ile 또는 Leu이고; R6은 Ala, Gly 또는 Ser이고; R7은 Ile, Leu 또는 Val 이고; R8은 Asp, Asn 또는 Glu이고; R10은 Phe, Tyr 또는 Trp이고; R12은 Arg, Asn, Lys 또는 His이고; R13은 Ile, Leu 또는 Val이고 ; R15은 Arg, Asn, Lys 또는 His이고; R16은 Leu, Ala, Ile 또는 Val이고; R18은 Phe, Asn, Lys 또는 His이고; R21은 Ile, Ala, Val 또는 Leu이고; R24은 OH, Ala 또는 Ser이다.
- 제1항에 있어서, R2가 Ala이고; R3이 Val이고; R4이 Lys이고; R5이 Val이고; R6이 Ala이고; R7이 Ile이고; R8이 Asp이고; R9이 Gly이고; R10이 Phe이고; R11이 Gly이고; R12이 Arg이고; R13이 Ile이고; R15이 Arg이고; R16이 Leu이고; R18이 Phe이고; R21이 Ile이고; R24이 OH인 유방염 백신 펩티드.
- 하기 일반식을 갖는 다중 항원성 제시 펩티드;상기 식에서, 펩티드1, 펩티드2, 펩티드3및 펩티드4는 하기 일반식의 화합물로부터 독립적으로 선택된다.;R1-R2-R3-R4-R5-R6-R7-R8-Gly-R10-Gly-R12-R13-Gly-R15-R16-Ala-R18-Arg-Ala-R21-Gln-Gly-R24상기 식에서, R1은 수소 또는 C1-C16카복실산이고: R2는 Ala, Gly, Ser 또는 프로피온산이고; R3은 Val, Ile, Leu 또는 D-Val이고; R4는 Lys 또는 Arg이고: R5는 Val, Ile 또는 Leu이고; R6은 Ala, Gly 또는 Ser이고; R7은 Ile, Leu 또는 Val 이고; R8은 Asp, Asn 또는 Glu이고; R10은 Phe, Tyr 또는 Trp이고; R12은 Arg, Asn, Lys 또는 His이고; R13은 Ile, Leu 또는 Val이고 ; R15은 Arg, Asn, Lys 또는 His이고; R16은 Leu, Ala, Ile 또는 Val이고; R18은 Phe, Asn, Lys 또는 His이고; R21은 Ile, Ala, Val 또는 Leu이고; R24은 OH, Ala 또는 Ser이다.
- 제3항에 있어서, 상기 펩티드1, 펩티드2, 펩티드3및 펩티드4가 각각, R2가 Ala이고, R3이 Val이고, R4이 Lys이고; R5이 Val이고, R6이 Ala이고; R7이 Ile이고, R8이 Asp이고; R9이 Gly이고; R10이 Phe이고; R11이 Gly이고; R12이 Arg이고; R13이 Ile이고; R15이 Arg이고; R16이 Leu이고; R18이 Phe이고; R21이 Ile이고; R24이 OH인 화합물로 이루어진 다중 항원성 제시 펩티드.
- 보조제내에 제1항의 화합물을 포함하는 약학 제제.
- 보조제내에 제3항의 화합물을 포함하는 약학 제제.
- (a) 미생물의 점착 및 비점착변종의 세포벽 또는 세포막 추출물을 준비하는 단계; 및 (b) 점착 변종에는 존재하지만 비점착 변종에는 존재하지 않는 분자를 결정하기 위해 단계(a)의 추출물을 비교하는 단계를 포함하는, 점착을 담당하는 분자를 결정하는 방법.
- 제7항에 있어서, 상기 미생물이 그람 양성 박테리아인 방법.
- 유방염과 연관된 제8항의 그람 양성 박테리아.
- 제7항의 방법에 따라 식별된 면역 펩티드를 포함하는 백신.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14776593A | 1993-11-05 | 1993-11-05 | |
| US08/147,765 | 1993-11-05 | ||
| PCT/US1994/012752 WO1995012410A1 (en) | 1993-11-05 | 1994-11-04 | Vaccine design and production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR960705582A true KR960705582A (ko) | 1996-11-08 |
Family
ID=22522813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960702306A KR960705582A (ko) | 1993-11-05 | 1994-11-04 | 백신 설계 및 제조 방법(vaccine design and production) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5679349A (ko) |
| EP (1) | EP0726774A4 (ko) |
| JP (1) | JPH09505039A (ko) |
| KR (1) | KR960705582A (ko) |
| CN (2) | CN1087953C (ko) |
| AU (1) | AU1050595A (ko) |
| BR (1) | BR9407988A (ko) |
| CA (1) | CA2175708A1 (ko) |
| CZ (1) | CZ128896A3 (ko) |
| FI (1) | FI961869A (ko) |
| HU (1) | HUT75556A (ko) |
| NO (1) | NO961808L (ko) |
| NZ (1) | NZ276290A (ko) |
| PL (1) | PL314303A1 (ko) |
| RO (1) | RO116045B1 (ko) |
| RU (1) | RU2143920C1 (ko) |
| SG (1) | SG49830A1 (ko) |
| TW (1) | TW448185B (ko) |
| UA (1) | UA42741C2 (ko) |
| WO (1) | WO1995012410A1 (ko) |
| ZA (1) | ZA948590B (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1089751A4 (en) * | 1998-06-23 | 2001-07-25 | Univ Leland Stanford Junior | ADJUVANTE THERAPY |
| JP2003171291A (ja) * | 1999-10-29 | 2003-06-17 | Takeda Schering-Plough Animal Health Kk | 乳房炎用粘膜予防剤 |
| US6984381B2 (en) | 2002-07-05 | 2006-01-10 | The United States Of America As Represented By The Secretary Of Agriculture | Vaccine for the prevention of bacterial infection of the bovine mammary gland |
| GB0219524D0 (en) | 2002-08-21 | 2002-10-02 | Queen Mary & Westfield College | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
| GB0802931D0 (en) | 2008-02-18 | 2008-03-26 | Queen Mary & Westfield College | Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions |
| CN102716475A (zh) * | 2012-06-29 | 2012-10-10 | 黑龙江省科学院微生物研究所 | 一种奶牛乳房炎疫苗的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0672123A1 (en) * | 1992-01-08 | 1995-09-20 | The Rockefeller University | Multifunctional surface protein of streptococci |
-
1994
- 1994-11-01 ZA ZA948590A patent/ZA948590B/xx unknown
- 1994-11-01 TW TW083110048A patent/TW448185B/zh not_active IP Right Cessation
- 1994-11-04 KR KR1019960702306A patent/KR960705582A/ko active IP Right Grant
- 1994-11-04 EP EP95901154A patent/EP0726774A4/en not_active Withdrawn
- 1994-11-04 PL PL94314303A patent/PL314303A1/xx unknown
- 1994-11-04 HU HU9601191A patent/HUT75556A/hu unknown
- 1994-11-04 CA CA002175708A patent/CA2175708A1/en not_active Abandoned
- 1994-11-04 RO RO96-00919A patent/RO116045B1/ro unknown
- 1994-11-04 AU AU10505/95A patent/AU1050595A/en not_active Abandoned
- 1994-11-04 SG SG1996007162A patent/SG49830A1/en unknown
- 1994-11-04 CN CN94194775A patent/CN1087953C/zh not_active Expired - Fee Related
- 1994-11-04 RU RU96112189A patent/RU2143920C1/ru active
- 1994-11-04 WO PCT/US1994/012752 patent/WO1995012410A1/en not_active Application Discontinuation
- 1994-11-04 UA UA96051776A patent/UA42741C2/uk unknown
- 1994-11-04 BR BR9407988A patent/BR9407988A/pt active IP Right Grant
- 1994-11-04 CZ CZ961288A patent/CZ128896A3/cs unknown
- 1994-11-04 JP JP7513446A patent/JPH09505039A/ja not_active Withdrawn
-
1996
- 1996-05-02 FI FI961869A patent/FI961869A/fi unknown
- 1996-05-03 NO NO961808A patent/NO961808L/no not_active Application Discontinuation
- 1996-07-03 US US08/678,444 patent/US5679349A/en not_active Expired - Fee Related
- 1996-07-04 NZ NZ276290A patent/NZ276290A/en unknown
-
2002
- 2002-03-11 CN CN02107123A patent/CN1380422A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NO961808L (no) | 1996-06-27 |
| EP0726774A1 (en) | 1996-08-21 |
| SG49830A1 (en) | 1998-06-15 |
| RU2143920C1 (ru) | 2000-01-10 |
| HUT75556A (en) | 1997-05-28 |
| PL314303A1 (en) | 1996-09-02 |
| WO1995012410A1 (en) | 1995-05-11 |
| CN1141000A (zh) | 1997-01-22 |
| CZ128896A3 (en) | 1996-10-16 |
| FI961869A0 (fi) | 1996-05-02 |
| UA42741C2 (uk) | 2001-11-15 |
| EP0726774A4 (en) | 2001-06-27 |
| CN1087953C (zh) | 2002-07-24 |
| BR9407988A (pt) | 1996-12-03 |
| CA2175708A1 (en) | 1995-05-11 |
| HU9601191D0 (en) | 1996-06-28 |
| JPH09505039A (ja) | 1997-05-20 |
| US5679349A (en) | 1997-10-21 |
| AU1050595A (en) | 1995-05-23 |
| RO116045B1 (ro) | 2000-10-30 |
| FI961869A (fi) | 1996-05-02 |
| TW448185B (en) | 2001-08-01 |
| CN1380422A (zh) | 2002-11-20 |
| NO961808D0 (no) | 1996-05-03 |
| NZ276290A (en) | 1997-11-24 |
| ZA948590B (en) | 1996-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Synthetic peptides analogous to the fimbrillin sequence inhibit adherence of Porphyromonas gingivalis | |
| CN100348266C (zh) | 小带素的肽拮抗剂及其用途 | |
| Sjöquist et al. | Protein A isolated from Staphylococcus aureus after digestion with lysostaphin | |
| KR900009095A (ko) | 합성 항원, 이의 제조방법 및 용도 | |
| FI961407A0 (fi) | Rokote Branhamella catarrhalista vastaan | |
| PT991761E (pt) | Mutantes novos de bactérias gram negativas das mucosas e a sua aplicação em vacinas. | |
| GB2178042A (en) | Antigenic peptides for fertility control | |
| AU7197096A (en) | Peptides of human papilloma virus for use in human T cell response inducing compositions | |
| CA2050749A1 (en) | Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations | |
| KR960703942A (ko) | 사람 융모막 고나도트로핀의 항원성을 갖는 화합물(Compounds having the antigenicity of hCG) | |
| WO2000054730A3 (en) | Compositions preparations and uses of human papillomavirus l1 protein | |
| DE69531241D1 (de) | Impfstoff gegen moraxella catarrhalis | |
| Kabat et al. | Immunochemical studies on blood groups. XXXIII. The effects of alkaline borohydride and of alkali on blood group A, B, and H substances | |
| Shinkai et al. | Amino acid sequence of cytochrome c 3 from Desulfovibrio vulgaris, Miyazaki | |
| AU2001267349A1 (en) | Pharmaceutical preparations comprising modified peptides | |
| KR960705582A (ko) | 백신 설계 및 제조 방법(vaccine design and production) | |
| AU1974992A (en) | Pseudomonas exoenzyme s peptide composition and method | |
| WO2005068632A8 (ja) | ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途 | |
| AU3036297A (en) | Identification and cloning of a mycobacterial antigen corresponding to a heparin-binding haemagglutinin | |
| Lichliter et al. | Basis for the design of anticandidal agents from studies of peptide utilization in Candida albicans | |
| Pugsley et al. | Comparison of colicins B-K260 and D-CA23: purification and characterization of the colicins and examination of colicin immunity in the producing strains | |
| Mori et al. | Physicochemical characterization of native and asialo human chorionic gonadotropin | |
| RU96112189A (ru) | Конструирование и получение вакцины | |
| CA2521038A1 (en) | Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production | |
| US4353822A (en) | Antigenic linear peptide compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| A107 | Divisional application of patent | ||
| E701 | Decision to grant or registration of patent right | ||
| NORF | Unpaid initial registration fee |